<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20210419051016N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2021-08-09</date_registration>
      <primary_sponsor>Esfahan University of Medical Sciences</primary_sponsor>
      <public_title>Evaluation of success &amp; failure of Mineral Trioxide Aggregate (MTA) &amp; Biodentine in pulp therapy of second mandibular primary molar with irreversible pulpitis</public_title>
      <acronym></acronym>
      <scientific_title>Comparative evaluation of clinical &amp; radiographic success &amp; failure rate of Mineral Trioxide Aggregate (MTA) &amp; Biodentine in pulp therapy of second mandibular primary molar with irreversible pulpitis in 3-6 years old children</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-07-11</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>50</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/57286</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: In the present study, simple allocation will be the method of choice for random allocation of the patients. In this method, the 'AB' order is considered for each odd number, and the 'BA' order is considered for each even number. Then a column is randomly selected from the table and if the first selected number is odd, the 'AB' order is applied which means the first patient is allocated in the A group and receives MTA treatment, and as a result, the next patient is allocated to the B group and receives Biodentine treatment. Similarly, If the selected number is even, the 'BA' order is applied and the first patient is allocated in the B group and receives Biodentine treatment, and as a result, the next patient is allocated to the A group and receives MTA treatment.
This is done 25 times until 25 samples are reached in each group, Blinding description: -Outcome assessor was not aware of the type of material used for each tooth while evaluating the treated teeth clinically and radiographically
-Patients were not aware of the type of material used for their treatment.</study_design>
      <phase>2-3</phase>
      <hc_freetext>Irreversible pulpitis of second mandibular primary molar.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group A: Firstly, periapical radiographic imaging with paralleling technique is provided using   Rinne XCP ( DENTSPLY, USA)  film holder and size 0 film with either E speed (Kodak, Ekta speed) or F speed (Kodak, insigne). Then proper local anesthesia injection is done using Lidocaine 2% and Epinephrine 1:80000 (Darou pakhsh, Tehran, Iran), and preparation of the tooth surface is done with 0.2% chlorhexidine (Shahre Daru, Tehran, Iran) is provided. after isolation with a rubber dam, coronal caries is removed using a sterile carbide round no.4 bur. Then, a high-speed 330 bur is used for removing the roof of the pulp chamber and access cavity preparation is completed. Afterward, by using a large round bur (no.6) coronal pulp tissue is removed completely from the canal orifices and the pulp chamber is then rinsed using sterile normal saline. Hemostasis is provided by applying saline-impregnated sterile cotton for 5 minutes. If bleeding is not controlled, the patient will be excluded from the study. To seal the canals and prevent bacterial invasion, the remaining pulp is covered with 2mm of MTA+ paste (CERKAMED Medical Company Poland) which is prepared by mixing the powder with sterile saline with 3:1 proportions. A layer of zonaline (Golchadent company) is placed as a provisional restoration. The patient will be recalled 7 days after treatment and if there would not be any sign or symptoms of treatment failure including pain, sensitivity to concussion, swelling, mobility, and fistula Stainless Steel Crown will provide the final restoration for the given tooth. Intervention 2: Intervention group B: Firstly, periapical radiographic imaging with paralleling technique is provided using   Rinne XCP ( DENTSPLY, USA)  film holder and size 0 film with either E speed (Kodak, Ekta speed) or F speed (Kodak, insigne). Then proper local anesthesia injection is done using Lidocaine 2% and Epinephrine 1:80000 (Darou pakhsh, Tehran, Iran), and preparation of the tooth surface is done with 0.2% chlorhexidine (Shahre Daru, Tehran, Iran) is provided. after isolation with a rubber dam, coronal caries is removed using a sterile carbide round no.4 bur. Then, a high-speed 330 bur is used for removing the roof of the pulp chamber and access cavity preparation is completed. Afterward, by using a large round bur (no.6) coronal pulp tissue is removed completely from the canal orifices and the pulp chamber is then rinsed using sterile normal saline. Hemostasis is provided by applying saline-impregnated sterile cotton for 5 minutes. If bleeding is not controlled, the patient will be excluded from the study. To seal the canals and prevent bacterial invasion, the remaining pulp is covered with 3 mm of Biodentine (Septodont, Saint-Maur-des-Fosses Cedex, France). A layer of zonaline (Golchadent company) is placed as a provisional restoration. The patient will be recalled 7 days after treatment and if there would not be any sign or symptoms of treatment failure including pain, sensitivity to concussion, swelling, mobility, and fistula Stainless Steel Crown will provide the final restoration for the given tooth.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
All data will be available

When:
Starting 6 months after publication

To whom:
Available for people working in academic institutions

Conditions:
No other conditions

Where to obtain:
Please send the request to "mona.esmaili.p@gmail.com"

How to obtain:
Documents will be sent in 1 week after receiving the request

Comments:
No more information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Dr. Maryam Hajiahmadi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Pediatric Dentistry department, Faculty of Dentistry, Isfahan University of Medical Sciences, Hezar-jerib St.</address>
        <city>Isfahan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>81746-73461</zip>
        <telephone>+98 31 3792 5539</telephone>
        <email>dr.maryamhajiahmadi@gmail.com</email>
        <affiliation>Esfahan University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr. Mona Esmaili</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Pediatric Dentistry department, Dentistry Faculty, Isfahan University of Medical Sciences, Hezar-jerib St.</address>
        <city>Isfahan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>81746-73461</zip>
        <telephone>+98 31 3792 5539</telephone>
        <email>mona.esmaili.p@gmail.com</email>
        <affiliation>Esfahan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>No underlying systematic diseases which leads to inhibition of local anesthesia injection
Having a  vital second mandibular primary molar tooth with deep caries lesion in the crown that is not extended subgingivally more than 1 mm
Having the history of typical pain related to the irreversible pulpitis (patient's chief complaint is spontaneous pain that lasts more than multiple seconds)
Sensitivity to thermal stimuli
All teeth are vital and the operator evaluates the pulp vitality by visual observation of pulp hemorrhage from all root canals of the intended tooth
Having access to the participant for 12-months follow-up
Pulp exposure due to severe carious crown
No pathologic mobility
No abscess, fistula, or swelling related to the intended tooth
Possibility of restoration with Stainless Steel Crown (SSC)
Possibility of providing hemostasis in the orifice entrance
No internal or pathologic external root resorption
No periapical radiolucency
No widening in the periodontal ligament
No radiolucency in furcation area
No calcific degeneration of the pulp
No root resorption more than 1/3 of the root length</inclusion_criteria>
      <agemin>3 years</agemin>
      <agemax>6 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Patients with underlying systemic disorders, physical, or mental disabilities
Presence of any clinical or radiographic sign of pulpal degeneration including severe hemorrhage from root canals that making hemostasis impossible in 5 minutes, internal root resorption,  bone resorption in furcation or preapical area, swelling or sinus tract formation, and pulp necrosis
Physiologic root resorption more than 2/3 of the root length (the sign of exfoliation)
Non-physiologic root resorption
Non-restorable tooth</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>K04.0</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Pulpitis</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group A: Firstly, periapical radiographic imaging with paralleling technique is provided using   Rinne XCP ( DENTSPLY, USA)  film holder and size 0 film with either E speed (Kodak, Ekta speed) or F speed (Kodak, insigne). Then proper local anesthesia injection is done using Lidocaine 2% and Epinephrine 1:80000 (Darou pakhsh, Tehran, Iran), and preparation of the tooth surface is done with 0.2% chlorhexidine (Shahre Daru, Tehran, Iran) is provided. after isolation with a rubber dam, coronal caries is removed using a sterile carbide round no.4 bur. Then, a high-speed 330 bur is used for removing the roof of the pulp chamber and access cavity preparation is completed. Afterward, by using a large round bur (no.6) coronal pulp tissue is removed completely from the canal orifices and the pulp chamber is then rinsed using sterile normal saline. Hemostasis is provided by applying saline-impregnated sterile cotton for 5 minutes. If bleeding is not controlled, the patient will be excluded from the study. To seal the canals and prevent bacterial invasion, the remaining pulp is covered with 2mm of MTA+ paste (CERKAMED Medical Company Poland) which is prepared by mixing the powder with sterile saline with 3:1 proportions. A layer of zonaline (Golchadent company) is placed as a provisional restoration. The patient will be recalled 7 days after treatment and if there would not be any sign or symptoms of treatment failure including pain, sensitivity to concussion, swelling, mobility, and fistula Stainless Steel Crown will provide the final restoration for the given tooth.</i_keyword>
      <i_keyword>Intervention group B: Firstly, periapical radiographic imaging with paralleling technique is provided using   Rinne XCP ( DENTSPLY, USA)  film holder and size 0 film with either E speed (Kodak, Ekta speed) or F speed (Kodak, insigne). Then proper local anesthesia injection is done using Lidocaine 2% and Epinephrine 1:80000 (Darou pakhsh, Tehran, Iran), and preparation of the tooth surface is done with 0.2% chlorhexidine (Shahre Daru, Tehran, Iran) is provided. after isolation with a rubber dam, coronal caries is removed using a sterile carbide round no.4 bur. Then, a high-speed 330 bur is used for removing the roof of the pulp chamber and access cavity preparation is completed. Afterward, by using a large round bur (no.6) coronal pulp tissue is removed completely from the canal orifices and the pulp chamber is then rinsed using sterile normal saline. Hemostasis is provided by applying saline-impregnated sterile cotton for 5 minutes. If bleeding is not controlled, the patient will be excluded from the study. To seal the canals and prevent bacterial invasion, the remaining pulp is covered with 3 mm of Biodentine (Septodont, Saint-Maur-des-Fosses Cedex, France). A layer of zonaline (Golchadent company) is placed as a provisional restoration. The patient will be recalled 7 days after treatment and if there would not be any sign or symptoms of treatment failure including pain, sensitivity to concussion, swelling, mobility, and fistula Stainless Steel Crown will provide the final restoration for the given tooth.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Frequency of incidence of pain in sealed second mandibular primary molar. Timepoint: 3, 6, and 12 months after treatment. Method of measurement: Patient is asked about a history of spontaneous pain after treatment (yes/no question).</prim_outcome>
      <prim_outcome>Frequency of incidence of sensitivity to concussion in sealed second mandibular primary molar. Timepoint: 3, 6, and 12 months after treatment سه، شش و 12 ماه پس از درمان. Method of measurement: Patient is asked about the presence of sensitivity while doing concussion test (yes/no question).</prim_outcome>
      <prim_outcome>Frequency of incidence of swelling in sealed second mandibular primary molar. Timepoint: 3, 6, and 12 months after treatment. Method of measurement: Patient is evaluated clinically for the presence of swelling (yes/no).</prim_outcome>
      <prim_outcome>Frequency of incidence of fistula formation in sealed second mandibular primary molar. Timepoint: 3, 6, and 12 months after treatment. Method of measurement: Patient is evaluated clinically for the presence of fistula (yes/no).</prim_outcome>
      <prim_outcome>Frequency of incidence of pathologic mobility in sealed second mandibular primary molar. Timepoint: 3, 6, and 12 months after treatment. Method of measurement: Patient is evaluated clinically for the presence of pathologic mobility (yes/no).</prim_outcome>
      <prim_outcome>Frequency of incidence of lucency around the root in radiographic imaging in sealed second mandibular primary molar. Timepoint: 6 and 12 months after treatment. Method of measurement: Patient is evaluated radiographically for the presence of lucency around the root (yes/no).</prim_outcome>
      <prim_outcome>Frequency of incidence of internal root resorption in radiographic imaging in sealed second mandibular primary molar. Timepoint: 6 and 12 months after treatment. Method of measurement: Patient is evaluated radiographically for the presence of internal root resorption.</prim_outcome>
      <prim_outcome>Frequency of incidence of external root resorption in radiographic imaging in sealed second mandibular primary molar. Timepoint: 6 and 12 months after treatment. Method of measurement: Patient is evaluated radiographically for the presence of external root resorption.</prim_outcome>
      <prim_outcome>Frequency of incidence of widening of the Periodontal Ligament (PDL) in radiographic imaging in sealed second mandibular primary molar. Timepoint: 6 and 12 months after treatment. Method of measurement: Patient is evaluated radiographically for the presence of widened PDL.</prim_outcome>
      <prim_outcome>Frequency of incidence of bone loss in radiographic imaging in sealed second mandibular primary molar. Timepoint: 6 and 12 months after treatment. Method of measurement: Patient is evaluated radiographically for the presence of bone loss.</prim_outcome>
      <prim_outcome>Frequency of incidence of loss of lamina dura in radiographic imaging in sealed second mandibular primary molar. Timepoint: 6 and 12 months after treatment. Method of measurement: Patient is evaluated radiographically for the presence of loss of lamina dura.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Esfahan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2021-05-26</approval_date>
        <contact_name>Ethics committee of Isfahan University of Medical Sciences</contact_name>
        <contact_address>Pediatric Dentistry department, Dentistry Faculty, Isfahan University of Medical Sciences, Hezar-jerib St. Isfahan Isfehan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
